Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio) filed its Monthly Return for the period ended 30 June 2026, confirming that no changes occurred in authorised or issued share capital during the month.

The registered capital remained at 1.03 billion shares, split between 260.30 million H shares listed in Hong Kong and 766.39 million A shares listed on the STAR Market in Shanghai.

Issued share counts were unchanged: • H shares: 260.30 million in issue, no treasury shares. • A shares: 765.58 million in issue with 0.82 million held in treasury.

Junshi Bio affirmed compliance with the Hong Kong Stock Exchange’s 5 % public-float requirement for its H-share class.

Equity incentive programmes were stable. Outstanding options totalled 37.91 million: • H-share scheme (adopted 29 Sep 2025): 13.21 million options outstanding; full exercise could add up to 64.23 million H shares. • A-share scheme (adopted 29 Sep 2025): 24.70 million options outstanding; full exercise could utilize the existing 0.82 million treasury shares.

No options were exercised, no warrants or convertibles are outstanding, and no other share movements were recorded. The company confirmed that all regulatory and listing requirements were met for the reporting period.